Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 11:40 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 10,627 matching trials from the live ClinicalTrials.gov search.

Filters: Pittsburgh, Pennsylvania Clear all

Conditions: Keratoconus
Interventions: riboflavin solution, placebo solution, KXL System; Drug · Device
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 12 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 11
States / cities: Irvine, California • San Diego, California • Indianapolis, Indiana + 8 more

Conditions: Radiation Retinopathy, Visual Impairment
Interventions: Faricimab, fluocinolone acetonide; Drug
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 29
States / cities: Palo Alto, California • Manchester, Connecticut • Tampa, Florida + 24 more

Conditions: Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: cixutumumab, temsirolimus, pharmacological study, laboratory biomarker analysis; Biological · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 1 Year to 21 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 21
States / cities: Birmingham, Alabama • Orange, California • Washington D.C., District of Columbia + 17 more

Conditions: Vestibular Diseases, Alzheimer Disease, Cognitive Impairment
Interventions: Vestibular Physical Therapy; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 60 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Smoking Cessation
Interventions: Transitional Tobacco Care Management (TTCM), eReferral to State Tobacco Quitline (QL), Nicotine replacement therapy; Behavioral · Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 1,416 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 3
States / cities: Boston, Massachusetts • Pittsburgh, Pennsylvania • Nashville, Tennessee

Conditions: Opioid-use Disorder, Pregnancy Related
Interventions: OUD; Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older · Female only
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Arthroplasty, Replacement, Knee, Anesthesia, Conduction, Acute Pain
Interventions: adductor canal block, SPANK, Ropivacaine; Procedure · Drug
Lead sponsor: Bruce Ben-David; Other
Eligibility: 19 Years to 90 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Herpes Zoster, Herpes Zoster Vaccine
Interventions: Herpes Zoster Vaccine GSK1437173A; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 50 Years and older
Enrollment: 7,539 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2024
U.S. locations: 25
States / cities: Phoenix, Arizona • Spring Valley, California • Hallandale, Florida + 18 more

Conditions: Respiratory Distress Syndrome, Adult
Interventions: Allogeneic Bone Marrow-Derived Human Mesenchymal Stromal Cells, Plasma-Lyte A; Biological
Lead sponsor: Michael A. Matthay; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 6
States / cities: San Francisco, California • Stanford, California • Boston, Massachusetts + 3 more

Conditions: Breast Cancer, Prostate Cancer, Lung Cancer
Interventions: Physician behavior related to Patient Preference Survey, Patient Preference Results; Behavioral · Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Obstetric Pain, Postpartum Depression, Breastfeeding, Pain, Acute, Pain, Chronic, Obstetric Anesthesia Problems, Drug Effect, Opioid Use
Interventions: Ketamine; Drug
Lead sponsor: Grace Lim, MD, MS; Other
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania

Conditions: Pancreatic Neoplasms, Metastases, Neoplasm
Interventions: GEMZAR, ALIMTA; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 40
States / cities: Huntsville, Alabama • Fountain Valley, California • Fullerton, California + 37 more

Conditions: Smoking
Interventions: Clinical Decision Support; Other
Lead sponsor: HealthPartners Institute; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 3
States / cities: Indianapolis, Indiana • Bloomington, Minnesota • Pittsburgh, Pennsylvania

Conditions: Systemic Sclerosis, Pulmonary; Hypertension
Interventions: Dimethyl Fumarate (DMF), Placebo Oral Tablet; Drug
Lead sponsor: Robert Lafyatis; Other
Eligibility: 18 Years to 80 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 4
States / cities: Denver, Colorado • Baltimore, Maryland • Boston, Massachusetts + 1 more

Conditions: Prostate Cancer
Interventions: tasquinimod, Placebo; Drug
Lead sponsor: Active Biotech AB; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,245 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 34
States / cities: Tucson, Arizona • Oxnard, California • Santa Monica, California + 31 more

Conditions: Delirium Superimposed on Dementia
Interventions: Aliviado DSD Caregiving Mastery Program; Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 2
States / cities: New York, New York • Pittsburgh, Pennsylvania

Conditions: Neoplasms, High Grade Glioma, Glioblastoma Multiforme, Malignant Glioma of Brain, Anaplastic Astrocytoma of Brain, High-grade Glioma, Anaplastic Glioma, Giant Cell Glioblastoma
Interventions: Biological G207; Biological
Lead sponsor: Pediatric Brain Tumor Consortium; Network
Eligibility: 3 Years to 21 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 5
States / cities: Aurora, Colorado • New York, New York • Pittsburgh, Pennsylvania + 1 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Canagliflozin, Placebo, Sitagliptin; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 678 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 24
States / cities: Phoenix, Arizona • Concord, California • Greenbrae, California + 21 more

Conditions: Human Papillomavirus Infection
Interventions: Quadrivalent human papillomavirus vaccine on-time administration, Quadrivalent human papillomavirus vaccine delayed administration; Biological
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 23 Years · Female only
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Ulcerative Colitis
Interventions: BMS-986165, Placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 31
States / cities: Bristol, Connecticut • Gainesville, Florida • New Port Richey, Florida + 25 more

Conditions: Cystic Fibrosis
Interventions: Investigator-designed lung transplant education resource (Research Intervention), Publicly available transplant education resource (Attention-control); Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 11
States / cities: Los Angeles, California • Denver, Colorado • New Haven, Connecticut + 8 more

Conditions: Depression, Depressive Disorder, Major, Depressive Disorder, Unipolar Depression, Major Depressive Disorder
Interventions: Venlafaxine XR, Aerobic Exercise, Lorazepam; Drug · Other
Lead sponsor: Kirk Erickson, PhD; Other
Eligibility: 60 Years to 79 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Solid Tumor
Interventions: BDTX-189; Drug
Lead sponsor: Black Diamond Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 24
States / cities: Scottsdale, Arizona • Long Beach, California • Orange, California + 20 more

Conditions: Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions: Avelumab, Talazoparib, Talazoparib Tosylate; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: Not listed
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 325
States / cities: Mobile, Alabama • Little Rock, Arkansas • Anaheim, California + 257 more

Search by objective public record fields.

Safety and Efficacy of Corneal Collagen Cross-Linking in Eyes With Keratoconus

Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of VA Loss Due to Radiation Retinopathy

Cixutumumab and Temsirolimus in Treating Younger Patients With Solid Tumors That Have Recurred or Not Responded to Treatment

Vestibular Physical Therapy for People With Alzheimer Disease

Post-Discharge Smoking Cessation Strategies: Helping HAND 4

Quantitative Sensory Psychophysical Correlates of Pain in Pregnant Women With OUD

Adductor Canal Vs Adductor Canal Plus SPANK Block for Postoperative Pain in Knee Arthroplasty Surgery

A Long-term Follow-up Study (ZOE-LTFU) of Two Studies 110390 (ZOSTER-006) and 113077 (ZOSTER-022) to Assess the Efficacy, Safety, and Immunogenicity Persistence of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine and Assessment of 1 or 2 Additional Doses in Two Subgroups of Older Adults

Human Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome (START)

Patient Preference Survey for Radiation Oncologists

Ketamine to Improve Recovery After Cesarean Delivery - Part 1

A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas.

Engaging Patients in Tobacco Cessation Resources in Dental Settings

Dimethyl Fumarate (DMF) in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension

A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer

Study of the Aliviado DSD Caregiving Mastery Program

HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma

The CANTATA-M (CANagliflozin Treatment and Trial Analysis - Monotherapy) Trial

Randomized Trial of Alternative Quadrivalent Human Papilloma Virus (HPV) Vaccination Schedules in a University Setting

Safety and Efficacy of Deucravacitinib in Participants With Moderate to Severe Ulcerative Colitis

Lung Transplant READY CF 2: A Multi-site RCT

A Multi-level Life-span Characterization of Adult-depression and Effects of Medication and Exercise

A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.

Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)